COVID Vaccines: What FDA Isn’t Talking About Ahead Of Upcoming Advisory Panel
From next-generation vaccine technology to safety data and global harmonization, what isn’t in the Vaccines and Related Biological Products Advisory Committee preview documents and on the 26 January meeting agenda may be just as important as what is.
You may also be interested in...
Vaccines and Related Biological Products Advisory Committee also said that more data is needed to determine the groups that potentially could receive more than one periodic vaccine booster.
US vaccine surveillance systems were triggered, but so far further investigation clears the bivalent COVID vaccine of any new safety concern. CDC and FDA’s attempt to control the narrative appears to have backfired, however, making what looks to be a non-issue more controversial than it needed to be due to limited public communication.
Marks opines on what sponsors would need to do to bring a ‘better’ vaccine to market in a NEJM interview. Meanwhile, CDC releases real world data on estimated bivalent booster efficacy.